Brainlab and Precision NeuroMed have a new strategic partnership for an artificial intelligence (AI)-enabled treatment planning platform. Once developed and commercialized, this platform will facilitate convection enhanced delivery (CED) to the brain.

There are long-standing limitations in this area of medicine, the companies say, due to the blood-brain barrier. For the most part, systemically administered drugs usually cannot reach therapeutic concentrations in the brain.

By standardizing and scaling delivery planning of targeted therapies directly into brain tissue, this collaboration can potentially overcome that. CED can provide precise concentrations of large-molecule drugs—simultaneously minimizing systemic exposure and off-target effects.

Brainlab and Precision NeuroMed Backgrounds

Brainlab, which is a digital medical technology company, has global experience in medical imaging digitalization, surgical workflow integration, and precision planning. Precision NeuroMed, meanwhile, is a clinical-stage biotechnology company whose proprietary molecular flow simulation software will integrate with Brainlab.

Together, the companies say they will create a cloud-based CED Treatment Planning System (CED TPS). Its initial development will focus on Precision NeuroMed’s lead investigational drug, PNM-201, for recurrent glioblastoma. This is an aggressive and often fatal form of brain cancer, currently with limited treatment options.

If the platform is able to expand, delivery of additional drugs and gene therapies could be possible. Potential treatments encompass a wide range of central nervous system disorders—epilepsy, Parkinson’s disease, Alzheimer’s disease, and ALS.

How AI Will Enable Innovation

CED TPS will use advanced imaging, simulation modeling, and AI-driven optimization to provide a personalized distribution experience for each patient. Under the terms of the agreement, Brainlab and Precision NeuroMed will collaborate on CED TPS’ development.

In addition, Brainlab has been granted an equity interest in Precision NeuroMed. This, the companies said, reflects a shared commitment to the technology’s long-term development and eventual adoption.